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doi:10.1016/j.jmii.2011.09.012A woman aged 56 years of age had a community-acquired left neck abscess and internal jugular
vein thrombosis with septicemia due to extended-spectrum b-lactamase (ESBL)eproducing
Klebsiella pneumoniae. Even though she was treated with intravenous meropenem, the bacter-
emia persisted. She was complicated with multiple brain abscesses, seizure, and leucopenia.
After a combination of intravenous fosfomycin and meropenem, her clinical condition became
stable. Combination treatment was continued for 2 months and she recovered. In individual
cases of Lemierre syndrome with brain abscess caused by ESBL-producing Enterobacteriaceae,
fosfomycin combination therapy may be the alternative choice.





an Society of Microbiology. PublIntroduction
Infections of the central nervous system (CNS) are critical
medical emergencies and require the administration of
antibiotics that are effective against resistant pathogens.ished by Elsevier Taiwan LLC. All rights reserved.
Brain abscess with fosfomycin combination therapy 73Lemierre syndrome is characterized by septicemia, internal
jugular vein (IJT) thrombosis, and metastatic septic emboli
secondary to acute pharyngeal infections.1 Fusobacterium
species is the most common cause, and Klebsiella pneu-
moniae is rarely reported in the literature.1,2 The lung is
the most common site for metastatic infections (79.8% of
cases).3 In contrast, metastatic infections involving the CNS
are rare. The successful treatment of multiple diffuse brain
abscesses depends on an appropriate choice of antimicro-
bial agents, particularly in patients who did not receive
surgical intervention.
Fosfomycin is a bactericidal antimicrobial agent with
high antibacterial activity against variable gram-positive
and gram-negative bacteria, especially multidrug-resistant
(MDR) pathogens.4 Fosfomycin had been proven to reach
effective concentrations in the cerebral-spinal fluid (CSF)
and brain tissue.5,6 Here we report the first case of Lemierre
syndrome complicating a diffuse brain abscess caused by
extended-spectrum b-lactamase (ESBL)-producing K pneu-
moniae that was successfully treated by intravenous (IV)
fosfomycin and meropenem combination therapy.Case report
A previously healthy woman aged 56 years was admitted to
our hospital with a 7-day history of fever, left neck swelling,
and headache. On admission, consciousness was clear and
her temperature was 39.4C. Her body weight was 68 kg with
moderate nutrition. Physical examinations showed a huge
mass about 12  8 cm in size with local heat, erythema, and
tenderness of left neck. White blood cell count was 17,200/
mm3 with 86% neutrophils. Serum level of C-reactive protein
was 33.5 mg/dl, and serum creatinine 0.8 mg/dl. Chest X-ray
and urinalysis were normal. Computed tomography of the
neck revealed left neck abscess and IJT thrombosis (Fig. 1A).
She received surgical debridement of the left neck abscess
on the second day of hospitalization and empirical therapy
with IV ceftazidime (2 g every 8 h) and metronidazole
(500 mg every 6 h) was administered.
On the fourth day of admission, pus and blood cultures
grew K pneumoniae. Since she had seizures and vomiting,
antimicrobial therapy was shifted to IV ceftriaxone (2 g every
12 h) and amikacin (375 mg every 12 h). Brain magnetic
resonance imaging (MRI) with gadolinium enhancementFigure 1. (A) contrasted computed tomography scan revealed a
with IJTthrombosis (thin arrowhead), (B) magnetic resonance imag(Fig. 1B) showed multiple brain abscesses. The patient and
family declined craniotomy and debridement because of
a high risk of severe sequelae.
On the fifth day of admission, the susceptibility study
revealed that K pneumoniae exhibited the ESBL phenotype.
For K pneumoniae isolate, minimal inhibition concentration
(MIC) of fosfomycin was 32 mg/ml and meropenem
MIC  1 mg/ml by microdilution method, then antibiotic
therapy was shifted to IV meropenem monotherapy (10 g
every 8 h). The patient remained febrile, but complained of
a headache. ESBL-producer bacteremia persisted after IV
meropenem treatment for 1 week, so IV fosfomycin (4 g
every 8 h) was supplemented. After the combination
regimen of IV fosfomycin and meropenem, blood cultures
became sterile and fever subsided. Combination treatment
was continued for two months without apparent toxicity.
The patient had no further evidence of metastatic infections
or neurologic sequelae. A follow-up brain MRI at 1 month
after discharge showed resolution of brain abscesses.Discussion
The CNS is rarely involved in metastatic infection in patients
with Lemierre syndrome, probably because the cerebral
veins are the upstream from the septic thrombi in the IJT.7,8
Because the patient did not receive craniotomy to debride
the brain abscesses, the most important strategy for our
patient with severe brain infections was the administration
of antibiotics to achieve effective concentrations in the CSF
and brain tissue.9 The development of b-lactam resistance
due to ESBL in K pneumoniae in the community-acquired
infections had increasingly emerged in recent years.10 So,
the choice of appropriate antibiotics for MDR pathogens is
a critical issue in the modern era of antibiotic resistance.
In a recent study about pharmacokinetic/pharmacody-
namic characters of fosfomycin by Pfausler et al,11 its
bactericidal activity against methicillin-susceptible Staphy-
lococcus aureus isolates causing the ventriculitis was
time-dependent. In contrast, the bactericidal activity of
fosfomycin against Enterobacteriaceae is concentration-
dependent.12 Both meropenem and fosfomycin can block
bacterial cell wall synthesis, but they work on different
steps of cell wall synthesis.13 Fosfomycin in combination
with meropenem for K pneumoniae revealed in vitrohuge subcutaneous abscess (thick arrowhead) of the left neck
ing scan revealed multiple brain abscesses.
74 W.-S. Lee et al.synergistic activity in the time-killing assays or by check-
erboard method.14 Fosfomycin was a hydrophilic antibiotic
with small molecular weight, can penetrate the blood-
brain-barrier (BBB), and achieve sufficient concentrations
to exert a significant antimicrobial effect.5,6,9 Fosfomycin
combined with lipophilic antimicrobial agents, such as the
fluoroquinolones, appears to effectively penetrate the BBB,
even when the inflamed meninges has been recovered and
healed. The simultaneous administration of b-lactams with
fosfomycin has currently been demonstrated to have
synergistic effects in vitro.15 However, fosfomycin is sug-
gested to be administered in combination with other
classes of antimicrobial agents to avoid the development of
bacterial resistance.16
To our knowledge, this patient is the first reported case of
Lemierre syndrome complicated by multiple brain abscesses
due to ESBL-producing K pneumoniae and who was success-
fully treated by fosfomycin combination therapy. In indi-
vidual cases of brain abscesses caused by ESBL-producing
Enterobacteriaceae pathogens, fosfomycin combination
therapy may be the alternative choice.References
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